Six months supplementation with conjugated linoleic acid induces regional-specific fat mass decreases in overweight and obese.
Long-term supplementation with conjugated linoleic acid (CLA) reduces body fat mass (BFM) and increases or maintains lean body mass (LBM). However, the regional effect of CLA was not studied. The study aimed to evaluate the effect of CLA per region and safety in healthy, overweight and obese adults. A total of 118 subjects (BMI: 28-32 kg/m2) were included in a double blind, placebo-controlled trial. Subjects were randomised into two groups supplemented with either 3 x 4 g/d CLA or placebo for 6 months. CLA significantly decreased BFM at month 3 (Delta=- 0 x 9 %, P=0 x 016) and at month 6 (Delta=- 3 x 4 %, P=0 x 043) compared with placebo. The reduction in fat mass was located mostly in the legs (Delta=- 0 x 8 kg, P<0 x 001), and in women (Delta=-1 x 3 kg, P=0 x 046) with BMI >30 kg/m2 (Delta=-1 x 9 kg, P=0 x 011), compared with placebo. The waist-hip ratio decreased significantly (P=0 x 043) compared with placebo. LBM increased (Delta=+0 x 5 kg, P=0 x 049) within the CLA group. Bone mineral content was not affected (P=0 x 70). All changes were independent of diet and physical exercise. Safety parameters including blood lipids, inflammatory and diabetogenic markers remained within the normal range. Adverse events did not differ between the groups. It is concluded that supplementation with CLA in healthy, overweight and obese adults decreases BFM in specific regions and is well tolerated.
Gaullier
Jean-Michel
JM
Link Medical Research AS, Kjeller, Norway. j-m@scr.no
Halse
Johan
J
Høivik
Hans Olav
HO
Høye
Kjetil
K
Syvertsen
Christian
C
Nurminiemi
Minna
M
Hassfeld
Cecilie
C
Einerhand
Alexandra
A
O'Shea
Marianne
M
Gudmundsen
Ola
O
D000273:Adipose Tissue / Q000187:drug effects* / Q000473:pathology; D000293:Adolescent; D000328:Adult; D000368:Aged; D000886:Anthropometry / Q000379:methods; D001823:Body Composition / Q000187:drug effects; D015992:Body Mass Index; D001835:Body Weight / Q000187:drug effects; D019587:Dietary Supplements; D004311:Double-Blind Method; D002149:Energy Intake / Q000187:drug effects; D015444:Exercise; D005260:Female; D006801:Humans; D044243:Linoleic Acids, Conjugated / Q000009:adverse effects / Q000627:therapeutic use*; D008055:Lipids / Q000097:blood; D008297:Male; D008875:Middle Aged; D009765:Obesity / Q000188:drug therapy* / Q000473:pathology; D050177:Overweight / Q000187:drug effects*; D049629:Waist-Hip Ratio; D015431:Weight Loss / Q000187:drug effects
D044243:Linoleic Acids, Conjugated; D008055:Lipids